Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch ...

In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...

The Phase 3 PEOPLE study evaluated the long-term effects of epicutaneous immunotherapy (EPIT) using the VIASKIN Peanut Patch, ...

"The vast majority of true allergic rhinitis ... with Allergy Therapeutics and serving as a chairperson of the AAAAI Foundation and on the World Allergy Organization board of directors.

The annual meeting of the American Academy of Allergy, Asthma & Immunology was held from Feb. 28 to March 3 in San Diego, ...

but can now point to a win for rilzabrutinib in chronic spontaneous urticaria (CSU). In a phase 2 trial, rilzabrutinib has been shown to rapidly reduce itch severity and significantly improve ...

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the ...

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...